• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Wilson James N

    6/12/25 8:44:25 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CORT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    WILSON JAMES N

    (Last) (First) (Middle)
    C/O CORCEPT THERAPEUTICS INCORPORATED
    101 REDWOOD SHORES PARKWAY

    (Street)
    REDWOOD CITY CA 94065

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    CORCEPT THERAPEUTICS INC [ CORT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/10/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock option (right to buy) $72.27 06/10/2025 A 25,000 (1) 06/10/2035 Common Stock 25,000 $0 25,000 D
    Explanation of Responses:
    1. Exercisable ratably in equal installments on each monthly anniversary of June 10, 2025 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date.
    Remarks:
    The power of attorney under which this form was signed is on file with the Commission.
    /s/ Joseph Douglas Lyon, as attorney-in-fact for James N. Wilson 06/12/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CORT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CORT

    DatePrice TargetRatingAnalyst
    11/6/2023$29.00 → $38.00Hold → Buy
    Truist
    4/11/2023$25.00Market Perform
    SVB Securities
    4/4/2023$27.00Overweight
    Piper Sandler
    2/15/2023$35.00 → $22.00Buy → Hold
    Jefferies
    8/1/2022$30.00Buy → Hold
    Truist
    7/27/2022$21.00 → $35.00Hold → Buy
    Jefferies
    6/27/2022$30.00 → $34.00Buy
    Canaccord Genuity
    2/2/2022$30.00Buy
    Canaccord Genuity
    More analyst ratings

    $CORT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Swisher Daniel N Jr exercised 2,200 shares at a strike of $14.08 and sold $156,376 worth of shares (2,200 units at $71.08) (SEC Form 4)

      4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)

      7/14/25 4:36:16 PM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Development Officer Guyer William exercised 100 shares at a strike of $21.65 and sold $7,350 worth of shares (100 units at $73.50) (SEC Form 4)

      4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)

      7/3/25 8:39:07 PM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Lyon Joseph Douglas exercised 100 shares at a strike of $13.56 and sold $7,350 worth of shares (100 units at $73.50) (SEC Form 4)

      4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)

      7/3/25 8:36:07 PM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CORT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

      Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for its proprietary, selective cortisol modulator, relacorilant, to treat patients with platinum-resistant ovarian cancer. Corcept's filing is based on positive data from its pivotal Phase 3 ROSELLA and Phase 2 trials. In these trials, patients who received relacorilant plus nab-paclitaxel experienced improved progression-free and overall survi

      7/14/25 8:00:00 AM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association's 85th Scientific Sessions with Simultaneous Publication in Diabetes Care

      Treatment with a cortisol modulator significantly improves glucose control in patients with hypercortisolism and difficult-to-control diabetes, accompanied by reductions in body weight, waist circumference and glucose-lowering medications CATALYST's prevalence phase identified hypercortisolism in 24 percent of patients with difficult-to-control type 2 diabetes Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented data from the randomized, double-blind, placebo-cont

      6/23/25 4:30:00 PM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting

      DAZALS did not meet its primary endpoint of improved outcome in the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients who received dazucorilant compared to patients who received placebo DAZALS met its secondary endpoint of improved overall survival at week 24 of the study in patients who received 300 mg of dazucorilant compared to patients who received placebo Exploratory analysis at the one-year mark shows continued significant improvement in overall survival between patients who received 300 mg of dazucorilant and those who received placebo only Corcept seeking guidance from United States and European regulators on optimum path forward Corcept Therapeutics Incorporat

      6/5/25 6:00:00 AM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CORT
    SEC Filings

    See more
    • SEC Form 8-K filed by Corcept Therapeutics Incorporated

      8-K - CORCEPT THERAPEUTICS INC (0001088856) (Filer)

      7/14/25 8:05:30 AM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corcept Therapeutics Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - CORCEPT THERAPEUTICS INC (0001088856) (Filer)

      6/16/25 4:47:28 PM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Corcept Therapeutics Incorporated

      144 - CORCEPT THERAPEUTICS INC (0001088856) (Subject)

      6/2/25 2:31:48 PM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CORT
    Leadership Updates

    Live Leadership Updates

    See more
    • Corcept Appoints Roberto Vieira as President, Oncology

      MENLO PARK, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the appointment of Roberto Vieira as President, Oncology. He will report to Joseph K. Belanoff, MD, Corcept's Chief Executive Officer, and join the company's Executive Team. Mr. Vieira joins Corcept from Mirati Therapeutics, Inc., where he served as Senior Vice President of U.S. Commercial until earlier this month. At Mirati, Mr. Vieira built the U.S. commercial o

      1/29/24 8:00:00 AM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corcept Appoints Monica Tellado as President, Emerging Markets

      MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism, and neurology disorders by modulating the effects of the hormone cortisol, today announced the appointment of Monica Tellado as President, Emerging Markets. She will report to Joseph K. Belanoff, MD, Corcept's Chief Executive Officer, and join the company's Executive Team. Ms. Tellado's prior role was at Heartflow, where she served as Chief Financial Officer. Before joining Heartflow, Ms. Tellado spent 19 years in ascending leadership roles at Gilead Science

      11/1/23 8:00:00 AM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corcept Therapeutics Announces Appointment of Three Senior Leaders

      MENLO PARK, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe endocrine, metabolic, oncologic and neurological disorders by modulating the effects of the hormone cortisol, today announced the appointment of three individuals to Commercial and Development leadership roles. Daniel Einhorn, MD, FACP, FACE, has joined Corcept as Vice President, Endocrine Strategy; Amiel Balagtas has joined as Vice President, Development Operations; and Lyndah Dreiling, MD, has joined as Vice President, Global Oncology Development. Dr. Einhorn will report to Sean Maduck, Presid

      4/7/22 4:05:00 PM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CORT
    Financials

    Live finance-specific insights

    See more
    • CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

      Revenue of $157.2 million, compared to $146.8 million in first quarter 2024 Reiterated 2025 revenue guidance of $900 – $950 million Net income per common share (diluted) of $0.17, compared to $0.25 in first quarter 2024 Cash and investments of $570.8 million as of March 31, 2025 Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat serious endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended March 31, 2025. Financial Results "In the first quarter, we had another record number of prescrip

      5/5/25 4:05:00 PM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL

      Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report first quarter financial results and provide a corporate update on May 5, 2025. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com. About Corcept Therapeutics For

      4/28/25 4:05:00 PM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update

      2024 revenue of $675.0 million, a 40 percent increase over 2023 2025 revenue guidance of $900 – $950 million 2024 net income of $141.2 million, a 33 percent increase over 2023 Cash and investments of $603.2 million as of December 31, 2024 Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2024. Financial Results "Once again, we had a record number of new Korlym® prescribers and a record number of p

      2/26/25 4:05:00 PM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CORT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Corcept Therapeutics upgraded by Truist with a new price target

      Truist upgraded Corcept Therapeutics from Hold to Buy and set a new price target of $38.00 from $29.00 previously

      11/6/23 7:25:25 AM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Securities initiated coverage on Corcept Therapeutics with a new price target

      SVB Securities initiated coverage of Corcept Therapeutics with a rating of Market Perform and set a new price target of $25.00

      4/11/23 7:25:02 AM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Corcept Therapeutics with a new price target

      Piper Sandler initiated coverage of Corcept Therapeutics with a rating of Overweight and set a new price target of $27.00

      4/4/23 7:17:46 AM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CORT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Corcept Therapeutics Incorporated (Amendment)

      SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)

      3/27/24 2:32:52 PM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Corcept Therapeutics Incorporated (Amendment)

      SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)

      2/14/24 4:23:00 PM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Corcept Therapeutics Incorporated (Amendment)

      SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)

      2/13/24 5:02:29 PM ET
      $CORT
      Biotechnology: Pharmaceutical Preparations
      Health Care